Normal tension glaucoma
Conditions
Interventions
Product Name: N/A
Product Code: N/A
Pharmaceutical Form:
Sponsors
HK Clinical Trials
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Newly diagnosed or existing NTG patients Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20
Exclusion criteria
Exclusion criteria: Any previous glaucoma surgery or laser
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Look at the effects of IOP reduction using SLT in the treatment of NTG. ;Secondary Objective: Look at the effects of IOP reduction using SLT in the treatment of NTG. ;Primary end point(s): Baseline IOP without glaucoma meds at 9am, 1pm, and 5pm Post SLT IOP at 1day, 1week, and every 3 months for 2 years (IOP will be measured at 9am, 1pm, and 5pm at 1 month, 3 months, 6 months, 1 year and 2 years) ;Timepoint(s) of evaluation of this end point: 1day, 1week, and every 3 months for 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Number of glaucoma meds pre-SLT and IOP with meds;Timepoint(s) of evaluation of this end point: n/a | — |
Countries
Hong Kong
Contacts
Public ContactDoctor Wai Yip Lee
HK Clinical Trials
Outcome results
None listed